

■ Time Table  
Day 3, February 20 (Sat)

As of February 17

	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	
Track 1		<div>SY22</div> <div>Tumor Agnostic Drug Development and Approval -A new Phase for Oncology Precision Medicine-</div> <div>8:00-10:00</div>			<div>O12</div> <div>Lower GI Tract (Colorectal Cancer)</div> <div>11:00-12:30</div>			<div>MeS19</div> <div>Management of relapsed or refractory FLT3-mutated AML</div> <div>13:30-14:20</div>		<div>PS2</div> <div>Presidential Session 2</div> <div>15:30-17:35</div>				<div>Highlight of the Day</div> <div>19:40-21:00</div>			
Track 2	<div>MeS03</div> <div>Current trends in immunotherapy for recurrent or metastatic head and neck cancer</div> <div>7:00-7:50</div>		<div>PSY4</div> <div>Facilitation of Asian Collaboration in Cancer Clinical Trials</div> <div>9:00-10:40</div>			<div>MO12</div> <div>Lymphoma</div> <div>11:40-12:35</div>			<div>MeS26</div> <div>The New Paradigm for METex14 skipping NSCLC: The MET-inhibitor TEPOTINIB</div> <div>14:30-15:20</div>		<div>MO19</div> <div>Trials in Progress</div> <div>17:20-18:15</div>				<div>SY28</div> <div>Future Prospects of Molecular Targeted Therapy for Lung Cancer Patients with Driver Mutations</div> <div>21:00-22:30</div>		
Track 3		<div>SY23</div> <div>Development and Future Perspectives of Immune Checkpoint Inhibitors for Breast Cancer</div> <div>8:00-10:00</div>				<div>MO10</div> <div>Tumor Agnostic Approach/ Immunotherapy</div> <div>11:00-11:55</div>		<div>MeS20</div> <div>Cancer immunotherapy for PD-L1 positive metastatic TNBC</div> <div>13:30-14:20</div>		<div>PSY6</div> <div>Challenges of Breast Cancer Research Collaboration Across Asia</div> <div>15:30-17:10</div>			<div>ES30</div> <div>Refining Treatment Decisions in mCRC</div> <div>18:50-19:40</div>		<div>SY29</div> <div>Antibody Drug Conjugates for Hematologic Malignancies</div> <div>21:00-23:00</div>		
Track 4	<div>MeS01</div> <div>Management of tumor lysis syndrome in the Era of novel and targeted cancer therapies</div> <div>7:00-7:50</div>		<div>MO5</div> <div>Upper GI Tract (Esophageal Cancer) 1</div> <div>9:00-10:00</div>			<div>O13</div> <div>NSCLC/TKI</div> <div>11:00-12:45</div>			<div>MeS27</div> <div>Molecularly targeted therapy for ALK-positive non-small-cell lung cancer (NSCL)</div> <div>14:30-15:20</div>		<div>MO18</div> <div>TR/Preclinical Oncology</div> <div>16:25-17:25</div>	<div>ES31</div> <div>Is precision medicine by type of driver mutation needed in lung cancer? An example of EGFR mutation, exon19 deletion and L858R</div> <div>18:50-19:40</div>					
Track 5		<div>JSMO</div> <div>Public Relations Committee Program</div> <div>8:00-9:00</div>			<div>JS3</div> <div>JSCN/JSMO Joint Symposium Multidisciplinary Initiatives in Genomic Medicine: Human Resource Development for Precision Medicine</div> <div>10:30-12:30</div>			<div>MeS21</div> <div>Optimal 1st and 2nd-Line Therapy for Metastatic Colorectal Cancer - Based on the personalized medicine -</div> <div>13:30-14:20</div>		<div>PSY7</div> <div>Current Status and Future Perspectives for Biliary Tract Cancer in Asian Countries</div> <div>15:30-17:10</div>			<div>ES32</div> <div>The utility of Comprehensive Genome Profiling for precision medicine</div> <div>18:50-19:40</div>		<div>PSY8</div> <div>Precision Oncology in Solid Cancer (II)</div> <div>21:00-22:30</div>		
Track 6	<div>MeS02</div> <div>Future Direction of cell-free DNA by NGS Testing for Precision Cancer Medicine</div> <div>7:00-7:50</div>		<div>SY24</div> <div>Palliative Care and Advance Care Planning</div> <div>9:00-10:00</div>			<div>PSY5</div> <div>New System of Board Certificated Specialist</div> <div>11:00-13:00</div>			<div>MeS28</div> <div>Cutting edge of immunotherapy in hematologic malignancies</div> <div>14:30-15:20</div>		<div>SY27</div> <div>A Novel Strategy for Treatment of Cancer Cachexia</div> <div>16:20-17:50</div>	<div>ES33</div> <div>Next generation of Her2 targeting therapy for gastric cancer</div> <div>18:50-19:40</div>					
Track 7		<div>Subcommittee for Teaching Staff Program</div> <div>8:00-9:20</div>			<div>SY25</div> <div>Employment Support from the Time of a Cancer Diagnosis</div> <div>10:30-12:30</div>		<div>MeS22</div> <div>The first step is crucial? How to support lung cancer patients: Balancing treatment and work</div> <div>13:30-14:20</div>			<div>MO15</div> <div>TR/Biomarker 3</div> <div>15:30-16:25</div>		<div>MO20</div> <div>Upper GI Tract (Esophageal Cancer) 2</div> <div>17:45-18:40</div>	<div>ES34</div> <div>Identifying targetable dependencies on pre-silenced BCL-2 family proteins using BCL profiling</div> <div>18:50-19:40</div>				
Track 8	<div>MeS04</div> <div>Novel 1st line ICI monotherapy for NSCLC Treatment strategy for advanced NSCLC recent topic</div> <div>7:00-7:50</div>		<div>MO6</div> <div>Multidisciplinary Team 1</div> <div>9:00-9:55</div>			<div>JS4</div> <div>JSPHO/JSMO Joint Symposium Medical Oncology for Children and AYA Patients: Comparison and Takeover</div> <div>11:00-13:00</div>			<div>MeS29</div> <div>Potentials of liquid biopsy in cancer treatment</div> <div>14:30-15:20</div>		<div>SP1</div> <div>Cancer Genome Net</div> <div>16:20-17:50</div>		<div>ES35</div> <div>Current perspective on the evolving treatments for Advanced / Metastatic Triple Negative Breast Cancer</div> <div>18:50-19:40</div>				
Track 9		<div>PSY2</div> <div>Patient Empowerment Program for Cancer Patients</div> <div>8:00-9:30</div>			<div>SY26</div> <div>Systemic Therapy for Advanced Hepatocellular Carcinoma - New Standards and Future Perspectives</div> <div>10:30-12:30</div>		<div>MeS23</div> <div>New Treatment Strategies for lung squamous cell cancer</div> <div>13:30-14:20</div>		<div>Medical Oncology Seminar</div> <div>15:20-18:40</div>				<div>ES36</div> <div>Evidence-based Utility of Multigene Assays in Clinical Practice</div> <div>18:50-19:40</div>				
Track 10	<div>MeS05</div> <div>Bosutinib - A New Treatment Option for CML Frontline Therapy</div> <div>7:00-7:50</div>		<div>O11</div> <div>Lung Cancer/Immunotherapy</div> <div>9:00-10:45</div>			<div>MO13</div> <div>Rare Cancer/ Cancer of Unknown Primary 1</div> <div>12:00-12:55</div>		<div>MeS30</div> <div>Evidence of Drug Therapy for Esophageal Cancer: Focus on nivolumab</div> <div>14:30-15:20</div>				<div>MO21</div> <div>NSCLC/ Locally Advanced</div> <div>17:45-18:40</div>					
Track 11		<div>PSY3</div> <div>ASCO-JSMO Breakthrough Meeting Insights Artificial Intelligence in Oncology and Therapeutics</div> <div>8:00-9:30</div>			<div>MO9</div> <div>TR/Genomic Profiling/Genomic Medicine</div> <div>10:30-11:40</div>		<div>MeS24</div> <div>Update on NSCLC Driver Gene Diagnostic Landscape</div> <div>13:30-14:20</div>		<div>MO16</div> <div>Patient Advocacy/ Survivorship</div> <div>15:30-16:25</div>		<div>O14</div> <div>Patient Advocacy/ Survivorship</div> <div>17:10-18:40</div>						
Track 12		<div>O9</div> <div>Gynecologic Cancer</div> <div>8:00-9:10</div>		<div>MO7</div> <div>Gynecologic Cancer</div> <div>10:00-10:25</div>		<div>MO11</div> <div>Breast Cancer/ Perioperative Therapy</div> <div>11:30-12:30</div>		<div>MeS25</div> <div>Understanding of antitumor T cell immunity and advances in NSCLC treatment</div> <div>13:30-14:20</div>	<div>MeS31</div> <div>Learn well about updated JBCS Guideline ~focusing on ER positive Her2 negative MBC~</div> <div>14:30-15:20</div>	<div>MO17</div> <div>Lower GI Tract</div> <div>15:30-16:25</div>		<div>MO22</div> <div>Rare Cancer/ Cancer of Unknown Primary 2</div> <div>17:45-18:40</div>					
Track 13		<div>O10</div> <div>Head and Neck Cancer</div> <div>8:00-9:30</div>			<div>MO8</div> <div>Head and Neck Cancer 2</div> <div>10:20-11:15</div>		<div>MO14</div> <div>TR/Biomarker 2</div> <div>12:30-13:25</div>		<div>MeS32</div> <div>Toward personalized combination cancer immunotherapy: Mechanisms of anti-tumor immunity and immunoresistance</div> <div>14:30-15:20</div>								
Track 14				<div>PAP</div> <div>Patient empowermentのための多職種連携</div> <div>10:00-10:50</div>		<div>PAP</div> <div>がんの疼痛診療</div> <div>11:00-11:50</div>		<div>PAP</div> <div>COVID-19ががん診療に与えた影響</div> <div>13:30-14:20</div>		<div>PAP</div> <div>ACP(アドバンスケア・プランニング)</div> <div>15:30-16:20</div>	<div>PAP</div> <div>PMDA hour</div> <div>16:30-17:20</div>	<div>PAP</div> <div>COVID-19とがん医療</div> <div>17:30-18:20</div>					
Meeting 1 (Pre-registration Required)		<div>ME06</div> <div>Two Types of HER2 Alterations, Amplification and Mutations, in Over Combinations with Neratinib and Trastuzumab-desuxetan</div> <div>8:00-9:00</div>				<div>ME13</div> <div>Improving Care and Outcomes for Cancer Survivors: an Australian Experience</div> <div>12:30-13:30</div>					<div>ME14</div> <div>Fostering Next Generation in Medical Oncology: ESMO Perspective</div> <div>16:30-17:30</div>				<div>ME15</div> <div>Changing Strategy of Systemic Treatment of AGC</div> <div>21:00-22:00</div>		
Meeting 2 (Pre-registration Required)			<div>ME07</div> <div>State-of-the-Art and Novel Molecular Targeted Therapies in Non-Small-Cell Lung Cancer</div> <div>9:00-10:00</div>			<div>ME12</div> <div>What is The Role of Immunotherapy for MBC? -Beyond TNBC-</div> <div>11:40-12:40</div>											
Meeting 3 (Pre-registration Required)			<div>ME08</div> <div>Novel Targets in Colorectal Cancer: BRAF, HER2, KRAS and Beyond</div> <div>9:00-10:00</div>			<div>ME11</div> <div>Novel Strategies Overcoming Resistance Mechanisms in Non-Small Cell Lung Cancer with Driver Oncogene Mutations</div> <div>11:30-12:30</div>											
Meeting 4 (Pre-registration Required)			<div>ME09</div> <div>Aiming to Overcome Immunotherapy Resistance</div> <div>9:00-10:00</div>														
	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	

Explanatory Notes

SP

=Special Session

AJS

=ASCO/JSMO Joint Symposium

EJS

=ESMO/JSMO Joint Symposium

SJS

=SIOG/JSMO Joint Symposium

APJS

=Asia-Pacific/JSMO Joint Symposium

JS

=Joint Symposium

PSY

=Presidential Symposium

SY

=Symposium

ME

=Meet the Experts

MoS

=Morning Seminar

MeS

=Medical Seminar

ES

=Evening Seminar

PS

=Presidential Session

O

=Oral Session

MO

=Mini-Oral Session

PD

=Poster Discussion Session

🗣

Simultaneous Interpretation (E&J)

🇬🇧

English Session

📺

Live Streaming Only

📺

Pre-recorded Video (streaming in the designated time only)

Explanatory Notes

SP =Special Session

AJS =ASCO/JSMO Joint Symposium

EJS =ESMO/JSMO Joint Symposium

SJS =SIOG/JSMO Joint Symposium

APJS =Asia-Pacific/JSMO Joint Symposium

JS =Joint Symposium

PSY =Presidential Symposium

SY =Symposium

ME =Meet the Experts

MoS =Morning Seminar

MeS =Medical Seminar

ES =Evening Seminar

PS =Presidential Session

O =Oral Session

MO =Mini-Oral Session

PD =Poster Discussion Session

Simultaneous Interpretation (E&J)

English Session

Live Streaming Only

Pre-recorded Video (streaming in the designated time only)